We think the stake in wide-moat Sartorius contributes to Bio-Rad’s moat. Although Bio-Rad does not have a controlling stake, Sartorius accounts for approximately 40% of Bio-Rad’s fair value in our ...

Thanks to budget cuts, many potential insights and treatments needed to propel oncology forward will never be realized.

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to recent findings by rare cancer researcher Dr. Taran Gujral, head of Fred Hutch's ...

Eighteen undergraduate nursing students are working as research assistants, and faculty and staff scholarly output has ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Meanwhile, William “Jamie” Tyler, Ph.D., professor and co-director of UAB’s Center for Neuroengineering and Brain Computer ...

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to ...

Explore the evolving landscape of clinical trials in drug discovery and learn about recent breakthroughs transforming the ...

Former NIH director Monica Bertagnolli and other scientists discussed the impact of reduced funding on cancer research and ...

We unpack the full scope of the U.S. budget cuts, from canceled clinical trials and stalled drug approvals to mass layoffs ...

Non-coding RNAs (ncRNAs), once considered the 'dark matter' of the genome, have now emerged as pivotal regulators in cancer ...

Although the definition of acute respiratory distress syndrome (ARDS) has undergone numerous revisions aimed at enhancing its ...